Day Traders, Penny Stocks, Stock Options, Futures and Forex

ANX @ OneMedForum Finance Conference on Jan 13

SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Principal Executive Officer, Brian M. Culley, will present at the OneMedForum Finance Conference on Wednesday, January 13, 2010, at 4:30 p.m. Pacific time. The conference will be held at the Sir Francis Drake Hotel in San Francisco.

Interested parties can access a live audio webcast on the ADVENTRX Pharmaceuticals Web site at ADVENTRX Pharmaceuticals. An archived presentation will be available on the Web site for 30 days.

LINK:
ADVENTRX Pharmaceuticals to Present at the OneMedForum Finance Conference on January 13 - Yahoo! Finance

When we get FDA approval and we are very close now this stock will be worth at least $5.00 to $10.00 a share based on the market cap of all the other pharma stocks


Institutional buyers link:

Adventrx Pharmaceuticals Inc (ANX)


ANX Conference 01.12.210 ADVENTRX Pharmaceuticals | OneMedPlace | Proprietary product candidates for the treatment of cancer.
Companies Presenting at the 2010 OneMedForum

This stock can go sometime above $20.00 over night
That would put his as a 30-45 bagger at todays price.

According to the Cancer Market Outlook report published by Business Insights, the market for cancer therapeutic drugs is expected to reach $40.9 billion by 2012. If approved by the U.S. Food and Drug Administration (FDA), the market for the Company’s drug candidates has a potential to reach more than $1.0 billion at market saturation.

Pharmaceutical companies with revenue of more than $1 billion include Cephalon Inc. (Nasdaq: CEPH), which trades at a market capitalization of $4.73 billion, and King Pharmaceuticals (Nasdaq: KG), which trades at a market capitalization of $3.15 billion. As of January 6, ANX trades at a market capitalization of $50.7 million.

The Company is in the process of commercializing two drug-therapy candidates in late stages of Food and Drug administration (FDA) clinical trials in the United States. The Company’s two candidates include ANX-530 (vinorelbine emulsion) and ANX-514 (docetaxel emulsion), formulated to enhance certain standard-of-care chemotherapy drugs. The Company also states that ANX-530 and ANX-514 are safer, more convenient and less expensive than Navelbine and Taxotere, two drug therapies currently marketed.

The Company’s strategy is to take advantage of an effective lifecycle-management technique of reformulating existing successfully marketed drug therapies. Of the top 50 pharmaceutical companies, more than 40% of all drug therapies produced have been reformulated to extend the life of existing marketed drugs between the years 2002 and 2005. Patent expirations and competition are threats to all pharmaceutical companies. Modified and improved existing products have become an important technique as a method of improving revenue stream for longer time periods.

The Company believes that chemotherapy drugs Navelbine and Taxotere have limitations that can be improved upon with its novel technologies. A new formulation of these two popular standard-of-care drug therapies is expected to reduce side-effects, negative results and medical complications of patients suffering from cancer.

The Company has attracted capital from Icahn Capital Management, Carl Icahn (as an individual), Barclays Global Investors UK Holdings, Vanguard Group among other well-know investors and group holding companies.

JP MORGAN ON OUR SIDE - To the Party soon - Nice $$$


ARTICLE 1/13/10 LINK - $1.85 soon!
Once Destined for Bankruptcy, Adventrx Pharmaceuticals Sets New Course With Reformulated Drugs | Xconomy

Here are some highlights:

As for the Internet rumors and investor hype that has accompanied the biotech’s resurrection, Culley says Adventrx has not funded any financial research and doesn’t “solicit those kinds of reports.” He adds that many Adventrx shareholders are individual investors who might not be as sophisticated as institutional investors. Still, Culley says, “The various reports and exceedingly high volume, I feel confident, are being driven by a compelling and attractive story.”

As for institutional investors, Culley acknowledges that Carl Icahn made a sizable investment in Adventrx in 2005 and still holds a roughly 3 percent stake in the company. Culley says Icahn is “one of our largest shareholders, and the only investment entity with a board seat.” That seat was filled for three years by Alex Denner, who also represents Icahn’s investment entities on the boards of Cambridge, MA-based Biogen Idec and San Diego’s Amylin Pharmaceuticals. But Culley says Denner resigned late last year “without disputes,” and “before the company started kind of waking up and running again.”

Culley noted that Icahn started investing in Adventrx when its common stock was trading at $1.85 a share. Since then, Adventrx has fallen as low as 3 cents a share. But Culley says, “I’d like to get him [Icahn] back in the black again.”


ANX @ OneMedForum Finance Conference on Jan 13

SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Principal Executive Officer, Brian M. Culley, will present at the OneMedForum Finance Conference on Wednesday, January 13, 2010, at 4:30 p.m. Pacific time. The conference will be held at the Sir Francis Drake Hotel in San Francisco.

Interested parties can access a live audio webcast on the ADVENTRX Pharmaceuticals Web site at ADVENTRX Pharmaceuticals. An archived presentation will be available on the Web site for 30 days.

LINK:
ADVENTRX Pharmaceuticals to Present at the OneMedForum Finance Conference on January 13 - Yahoo! Finance

When we get FDA approval and we are very close now this stock will be worth at least $5.00 to $10.00 a share based on the market cap of all the other pharma stocks


Institutional buyers link:

Adventrx Pharmaceuticals Inc (ANX)


ANX Conference 01.12.210 ADVENTRX Pharmaceuticals | OneMedPlace | Proprietary product candidates for the treatment of cancer.
Companies Presenting at the 2010 OneMedForum

This stock can go sometime above $20.00 over night
That would put his as a 30-45 bagger at todays price.

According to the Cancer Market Outlook report published by Business Insights, the market for cancer therapeutic drugs is expected to reach $40.9 billion by 2012. If approved by the U.S. Food and Drug Administration (FDA), the market for the Company’s drug candidates has a potential to reach more than $1.0 billion at market saturation.

Pharmaceutical companies with revenue of more than $1 billion include Cephalon Inc. (Nasdaq: CEPH), which trades at a market capitalization of $4.73 billion, and King Pharmaceuticals (Nasdaq: KG), which trades at a market capitalization of $3.15 billion. As of January 6, ANX trades at a market capitalization of $50.7 million.

The Company is in the process of commercializing two drug-therapy candidates in late stages of Food and Drug administration (FDA) clinical trials in the United States. The Company’s two candidates include ANX-530 (vinorelbine emulsion) and ANX-514 (docetaxel emulsion), formulated to enhance certain standard-of-care chemotherapy drugs. The Company also states that ANX-530 and ANX-514 are safer, more convenient and less expensive than Navelbine and Taxotere, two drug therapies currently marketed.

The Company’s strategy is to take advantage of an effective lifecycle-management technique of reformulating existing successfully marketed drug therapies. Of the top 50 pharmaceutical companies, more than 40% of all drug therapies produced have been reformulated to extend the life of existing marketed drugs between the years 2002 and 2005. Patent expirations and competition are threats to all pharmaceutical companies. Modified and improved existing products have become an important technique as a method of improving revenue stream for longer time periods.

The Company believes that chemotherapy drugs Navelbine and Taxotere have limitations that can be improved upon with its novel technologies. A new formulation of these two popular standard-of-care drug therapies is expected to reduce side-effects, negative results and medical complications of patients suffering from cancer.

The Company has attracted capital from Icahn Capital Management, Carl Icahn (as an individual), Barclays Global Investors UK Holdings, Vanguard Group among other well-know investors and group holding companies.

Carl Icahn - Current Portfolio thru 9-30-09 (ANX Holding)
Carl Icahn Portfolio Holdings -- GuruFocus.com

Link to pre-market:

ADVENTRX Pharmaceuticals, Inc. (ANX) Pre-Market Trading

Stock Market Analysis: Stocks to Buy 1/13/10 January 13, 2010

Adventrx Pharmaceuticals, Inc. (ANX) - Adventrx Pharmaceuticals stock managed to trade above $0.50 briefly on Tuesday. Resistance is now located at $0.52. A close above $0.50 with heavy volume would be very bullish. This stock could break out big with any positive news.


nice.

This newsletter is definitely from a group of penny stock experts.

#1 Newsletter